- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00316576
Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)
January 16, 2008 updated by: University Hospital, Caen
Evaluation of the Impact of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Development of Acute Renal Failure in Critically Ill Patients
Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated.
Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated.
Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.
Study Type
Observational
Enrollment (Anticipated)
160
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Caen, France, 14000
- Medical Intensive care Unit; Caen University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Consecutive patients admitted to ICU fore more than 48 hours
Description
Inclusion Criteria:
- Age > 18 yrs
- ICU stay > 48 hours
Exclusion Criteria:
- Age < 18 yrs
- Creatinine > 180 µmol/L
- Absence of consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of ARF
Time Frame: During ICU stay
|
During ICU stay
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality
Time Frame: ICU and Hospital mortality
|
ICU and Hospital mortality
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Damien du Cheyron, MD, University Hospital, Caen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Study Completion (Actual)
November 1, 2006
Study Registration Dates
First Submitted
April 19, 2006
First Submitted That Met QC Criteria
April 19, 2006
First Posted (Estimate)
April 21, 2006
Study Record Updates
Last Update Posted (Estimate)
January 17, 2008
Last Update Submitted That Met QC Criteria
January 16, 2008
Last Verified
January 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-130
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Illness
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedNeonatal Critical Illness | Pediatric Critical IllnessUnited States
-
Yale UniversityNational Institute on Aging (NIA)RecruitingCritical Illness | Illness, CriticalUnited States
-
McMaster UniversityLondon Health Sciences Centre; McMaster Children's Hospital; Canadian Critical...CompletedPediatric Critical IllnessCanada
-
Boston Children's HospitalCompleted
-
St Helens & Knowsley Teaching Hospitals NHS TrustManchester University NHS Foundation TrustCompleted
-
Sándor BeniczkyUniversity of Aarhus; Danish Council for Independent Research; Søster og Verner...CompletedCritical Illness Myopathy | Myopathy Critical IllnessDenmark
-
Hospital de Clinicas de Porto AlegreUnknownCritical Illness PolyneuropathiesBrazil
-
Peking Union Medical College HospitalBaxter Healthcare CorporationUnknownNutrition Therapy for Critical Illness
-
Assistance Publique - Hôpitaux de ParisRecruitingCritical Illness Related Corticosteroids InsufficiencyFrance
-
Yuzuncu Yıl UniversityKahramanmaras Sutcu Imam University; Izmir Ataturk Training and Research HospitalCompleted
Clinical Trials on Blood sampling for PCR
-
Kyorin UniversityCompletedMicroRNA Expression Profile in Human VitreousJapan
-
Institut du Cancer de Montpellier - Val d'AurelleLigue contre le cancer, FranceRecruiting
-
University of AthensUniversity of Jena; General Hospital of LamiaCompleted
-
Central Hospital, Nancy, FranceCompletedDiastolic Heart Failure
-
University Hospital, RouenUniversity Hospital, Caen; OncoDiagNot yet recruitingColorectal CancerFrance
-
JaxBio LtdTel Aviv University; Tel Aviv Medical Center; Vilnius University Hospital Santaros... and other collaboratorsRecruitingHematologic MalignancyIsrael, Greece, Czechia, Lithuania
-
University Hospital, RouenUnknownMetastatic Colorectal Cancer | Circulating MarkersFrance
-
University Hospital, BordeauxCompletedPain | Fabry's DiseaseFrance